COVID-19 update included
The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic

The Europe Cancer Registry Software Market would witness market growth of 9.85% CAGR during the forecast period (2019-2025).
Cancer is a significant national responsibility. Cancer is the second leading cause of mortality in the United States. Every year, cancer-cost is one of the largest costs in Healthcare spending and loss of productivity due to illness and death. Reducing the cancer burden of the country is a great and noble cause involving many people, such as researchers, physicians, epidemiologists, public health planners, medical students, legislators, and others. In Europe, cancer registration is hindered by substantial differences in the consistency and scope of CRs, by inadequate harmonization and comparability of procedures and data, by heterogeneous legislation that restricts CR’s ability to network, cooperate and engage in research. They arise against the backdrop of large variations in national economic, legislative, social and cultural contexts.
Important measures have been taken at the level of the European Union (EU) in recent years to map out and understand these problems, to identify best practices and to formulate sound recommendations, and also to develop policy mechanisms and tools for cooperation and information sharing. However, since cancer has now become Europe’s second-largest cause of death, one-third of the population still lacks reliable cancer identification, mostly in low-resource and health-status regions. It is therefore important that efforts to support the advancement of CRs continue and that the wealth of expertise and vision gained in this field is transformed into practice.
Based on Type, the market is segmented into Integrated and Standalone. Based on Deployment Type, the market is segmented into On-premise and Cloud-based. Based on Component, the market is segmented into Commercial and Public. Based on End User, the market is segmented into Government & Third party, Research Centers, Hospital & Medical Centers, Private Payers and Pharma Biotech & Medical Device Suppliers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include IBM Corporation, McKesson Corporation, Conduent, Incorporated, Elekta AB, Ordinal Data, Inc., Onco, Inc., C/Net Solutions, Rocky Mountain Cancer Data System, Electronic Registry System, Inc., and Himagine Solutions, Inc.
Scope of the Study
Market Segmentation:
By Type

  • Integrated
  • Standalone


By Deployment Type

  • On-premise
  • Cloud-based


By Component

  • Commercial
  • Public


By End User

  • Government & Third party
  • Research Centers
  • Hospital & Medical Centers
  • Private Payers
  • Pharma Biotech & Medical Device Suppliers


By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe


Companies Profiled

  • IBM Corporation
  • McKesson Corporation
  • Conduent, Incorporated
  • Elekta AB
  • Ordinal Data, Inc.
  • Onco, Inc.
  • C/Net Solutions
  • Rocky Mountain Cancer Data System
  • Electronic Registry System, Inc.
  • Himagine Solutions, Inc.


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free